A machine learning approach to identify predictive molecular markers for cisplatin chemosensitivity following surgical resection in ovarian cancer
Authors:
Open Access
- 19 August 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Abstract
Ovarian cancer is associated with poor prognosis. Platinum resistance contributes significantly to the high rate of tumour recurrence. We aimed to identify a set of molecular markers for predicting platinum sensitivity. A signature predicting cisplatin sensitivity was generated using the Genomics of Drug Sensitivity in Cancer and The Cancer Genome Atlas databases. Four potential biomarkers (CYTH3, GALNT3, S100A14, and ERI1) were identified and optimized for immunohistochemistry (IHC). Validation was performed on a cohort of patients (n = 50) treated with surgical resection followed by adjuvant carboplatin. Predictive models were established to predict chemosensitivity. The four biomarkers were also assessed for their ability to prognosticate overall survival in three ovarian cancer microarray expression datasets from The Gene Expression Omnibus. The extreme gradient boosting (XGBoost) algorithm was selected for the final model to validate the accuracy in an independent validation dataset (n = 10). CYTH3 and S100A14, followed by nodal stage, were the features with the greatest importance. The four gene signature had comparable prognostication as clinical information for two-year survival. Assessment of tumour biology by means of gene expression can serve as an adjunct for prediction of chemosensitivity and prognostication. Potentially, the assessment of molecular markers alongside clinical information offers a chance to further optimise therapeutic decision making.Keywords
Funding Information
- SingHealth Duke-NUS Academic Medical Centre
- National Medical Research Council (NMRC/TA/0061/2017)
- NCCS Cancer Fund
This publication has 32 references indexed in Scilit:
- BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group StudyBritish Journal of Cancer, 2013
- Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancerBMC Cancer, 2010
- Optimal treatment for relapsing ovarian cancerAnnals of Oncology, 2010
- Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2010
- Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinomaGynecologic Oncology, 2010
- Treatment for Recurrent Ovarian Cancer—At First RelapseJournal of Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The Second World Cancer Research Fund/American Institute for Cancer Research Expert Report. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global PerspectiveProceedings of the Nutrition Society, 2008
- Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple TreatmentsJNCI: Journal of the National Cancer Institute, 2006
- Chemotherapy Sensitivity and Resistance Assays: A Systematic ReviewJournal of Clinical Oncology, 2004